Short Interest in Evaxion Biotech A/S (NASDAQ:EVAX) Decreases By 22.0%

Evaxion Biotech A/S (NASDAQ:EVAX) was the recipient of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 52,600 shares, a decline of 22.0% from the October 15th total of 67,400 shares. Based on an average trading volume of 47,600 shares, the days-to-cover ratio is currently 1.1 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Evaxion Biotech A/S stock. Armistice Capital LLC increased its holdings in Evaxion Biotech A/S (NASDAQ:EVAX) by 6.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 392,000 shares of the company’s stock after acquiring an additional 25,000 shares during the quarter. Armistice Capital LLC owned about 7.24% of Evaxion Biotech A/S worth $1,137,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 11.04% of the company’s stock.

Evaxion Biotech A/S Trading Down 14.3 %

NASDAQ EVAX traded down $0.24 during trading on Friday, hitting $1.44. The company had a trading volume of 76,290 shares, compared to its average volume of 28,397. The company has a quick ratio of 2.80, a current ratio of 1.00 and a debt-to-equity ratio of 7.99. Evaxion Biotech A/S has a one year low of $1.40 and a one year high of $13.61. The company’s fifty day moving average is $2.77 and its 200-day moving average is $3.06.

Evaxion Biotech A/S (NASDAQ:EVAX) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.08. The business had revenue of $3.02 million during the quarter, compared to the consensus estimate of $0.19 million. Equities research analysts expect that Evaxion Biotech A/S will post -0.15 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of Evaxion Biotech A/S in a report on Friday, November 1st.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.